Asset profile
peginterferon alfa-2a (Pegasys)
Unknown / undisclosed
Evidence outlook
Approved: Chronic Hepatitis B
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
46 competitors in this universe: 2 direct rivals (same mechanism and indication), 5 same-class, 39 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Peginterferon Alfa-2a (Pegasys): this drug | Approved | — | Type I interferon receptor | ||
| Interferon Alfa-2b (Intron A) | Approved | — | Type I interferon receptor | ||
| Human Serum Albumin / Interferon Alpha2b Fusion Protein | Phase 1/2 | Biologic (subtype unspecified) | Type I interferon receptor | ||
| Anifrolumab | Approved | Monoclonal antibody | Type I interferon receptor, Type I interferon receptor subunit 1 (IFNAR1) | ||
| Interferon Beta-1b | Approved | Biologic (subtype unspecified) | Interferon beta receptor (type I IFN signaling), Type I interferon receptor | ||
| Interferon-Beta1 | Approved | Biologic (subtype unspecified) | Type I interferon receptor | ||
| Peginterferon Beta-1a (Plegridy) | Approved | Biologic (subtype unspecified) | Type I interferon receptor, Interferon beta receptor (type I IFN signaling) | ||
| Rebif (interferon Beta 1a) | Approved | Biologic (subtype unspecified) | Interferon beta receptor (type I IFN signaling), Type I interferon receptor | ||
| Adefovir Dipivoxil (Hepsera) | Approved | Small molecule | — | ||
| Entecavir (Baraclude) | Approved | Small molecule | — | ||
| Hepatitis B Immune Globulin (HepaGam B) | Approved | Small molecule | — | ||
| Lamivudine (Epivir-HBV) | Approved | — | — | ||
| Telbivudine (Tyzeka) | Approved | — | — | ||
| Tenofovir Alafenamide (Vemlidy) | Approved | Small molecule | — | ||
| Tenofovir Disoproxil Fumarate (Viread) | Approved | Small molecule | HIV reverse transcriptase (RT) | ||
| Diluted I.V.-Hepabig inj(GC5103) | Phase 3 | Biologic (subtype unspecified) | — |
…and 31 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.